These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12632504)

  • 21. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
    Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients.
    Schirrmacher V
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28531117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant paramyxovirus type 1-avian influenza-H7 virus as a vaccine for protection of chickens against influenza and Newcastle disease.
    Swayne DE; Suarez DL; Schultz-Cherry S; Tumpey TM; King DJ; Nakaya T; Palese P; Garcia-Sastre A
    Avian Dis; 2003; 47(3 Suppl):1047-50. PubMed ID: 14575108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection induced by infectious laryngotracheitis virus vaccines alone and combined with Newcastle disease virus and/or infectious bronchitis virus vaccines.
    Vagnozzi A; García M; Riblet SM; Zavala G
    Avian Dis; 2010 Dec; 54(4):1210-9. PubMed ID: 21313841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression.
    Mohebbi A; Ebrahimzadeh MS; Baghban Rahimi S; Saeidi M; Tabarraei A; Mohebbi SR; Shirian S; Gorji A; Ghaemi A
    Virus Res; 2019 Feb; 261():72-80. PubMed ID: 30599161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor cell vaccine combined with Newcastle disease virus promote immunotherapy of lung cancer.
    Wang H; Nan F; Zeng Z; Zhang X; Ke D; Zhang S; Zhou X; Niu D; Fan T; Jiang S; Zhang X; Wang Y; Wang B; Zhang W
    J Med Virol; 2023 Feb; 95(2):e28554. PubMed ID: 36738232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits.
    Uyl-de Groot CA; Vermorken JB; Hanna MG; Verboom P; Groot MT; Bonsel GJ; Meijer CJ; Pinedo HM
    Vaccine; 2005 Mar; 23(17-18):2379-87. PubMed ID: 15755632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine.
    Herold-Mende C; Karcher J; Dyckhoff G; Schirrmacher V
    Adv Otorhinolaryngol; 2005; 62():173-83. PubMed ID: 15608427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
    Schirrmacher V
    Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme.
    Schneider T; Gerhards R; Kirches E; Firsching R
    J Neurooncol; 2001 May; 53(1):39-46. PubMed ID: 11678429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of adjuvants on in ovo vaccination against Newcastle disease on hatchability, performance and antibody titres in commercial pullets.
    Soleimani Roudi P; Golian A; Haghparast A; Bassami MR; Majidzadeh Heravi R
    J Anim Physiol Anim Nutr (Berl); 2018 Aug; 102(4):977-985. PubMed ID: 29740890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant-attenuated
    Ding K; Shang K; Yu ZH; Yu C; Jia YY; He L; Liao CS; Li J; Zhang CJ; Li YJ; Wu TC; Cheng XC
    J Vet Sci; 2018 Mar; 19(2):232-241. PubMed ID: 29032660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenicity and immunogenicity of different recombinant Newcastle disease virus clone 30 variants after in ovo vaccination.
    Ramp K; Topfstedt E; Wäckerlin R; Höper D; Ziller M; Mettenleiter TC; Grund C; Römer-Oberdörfer A
    Avian Dis; 2012 Mar; 56(1):208-17. PubMed ID: 22545548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
    Lotem M; Merims S; Frank S; Hamburger T; Nissan A; Kadouri L; Cohen J; Straussman R; Eisenberg G; Frankenburg S; Carmon E; Alaiyan B; Shneibaum S; Ozge Ayyildiz Z; Isbilen M; Mert Senses K; Ron I; Steinberg H; Smith Y; Shiloni E; Gure AO; Peretz T
    J Immunol Res; 2016; 2016():8121985. PubMed ID: 27294163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-tumor vaccination].
    Schirrmacher V
    Zentralbl Chir; 2000; 125 Suppl 1():33-6. PubMed ID: 10929644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction between a live avian pneumovirus vaccine and two different Newcastle disease virus vaccines in broiler chickens with maternal antibodies to Newcastle disease virus.
    Ganapathy K; Todd V; Cargill P; Montiel E; Jones RC
    Avian Pathol; 2006 Dec; 35(6):429-34. PubMed ID: 17121730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study on immune efficacy of Newcastle disease chitosan microsphere vaccine].
    Zhai RL; Xu HY; Wang YL; Qin ZM; Jiang SJ
    Wei Sheng Wu Xue Bao; 2007 Aug; 47(4):692-6. PubMed ID: 17944374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial.
    Cho DY; Yang WK; Lee HC; Hsu DM; Lin HL; Lin SZ; Chen CC; Harn HJ; Liu CL; Lee WY; Ho LH
    World Neurosurg; 2012; 77(5-6):736-44. PubMed ID: 22120301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tween 80-solubilized Newcastle disease virus prepared as a water-in-oil-in-water vaccine.
    Cajavec S; Bidin Z; Sladić D; Pokrić B
    Avian Dis; 1996; 40(1):193-201. PubMed ID: 8713034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies.
    Haas C; Schirrmacher V
    Cancer Immunol Immunother; 1996 Nov; 43(3):190-4. PubMed ID: 9001573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.